Windtree Receives SBIR Grant in Continued Support of AEROSURF® Phase 2b Clinical Trial

WARRINGTON, Pa., May 22, 2017 /PRNewswire/ — Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has been awarded $0.9 million under a previously announced Phase II Small Business Innovation Research Grant (SBIR) valued at up to $2.6 million from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to support the AEROSURF® phase 2b clinical trial in respiratory distress syndrome (RDS). Windtree was awarded an initial $1.0 million under this grant in August 2016, and over the next year may be awarded up to an additional $0.7 million through the completion of the phase 2b clinical trial and one-year patient follow-up.